US Alzheimer's Blood Tests Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$141.8 MnPlaceholder estimate
Estimate 2025$174.6 Mn37.2% of the global market
Projected 2034$1.13 Bn 549.1%Adds $958.6 Mn over 9 forecast years
CAGR 2025–203423.1%Faster than 97% of 180 Medical Devices markets here
Key players5
US is 37.24% of the global market.
In North America, the largest is US (this report) at $174.6 Mn.
40 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Alzheimer's Blood Tests Market Analysis Executive Summary
Alzheimer's blood tests measure proteins such as p-tau and amyloid in blood to help diagnose Alzheimer's disease without a brain scan.
Key segments of the alzheimer's Blood Tests market include biomarker (p-Tau217, Amyloid Beta 42/40 and Neurofilament Light) and use (Diagnosis, Clinical Trial Screening and Monitoring).
US Alzheimer's Blood Tests market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Alzheimer's Blood Tests Market Dynamics
Market Growth Drivers
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the alzheimer's Blood Tests market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the alzheimer's Blood Tests market.
Competitive Landscape for Alzheimer's Blood Tests Market in the US
The alzheimer's Blood Tests market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Alzheimer's Blood Tests Market in the US
Alzheimer's Blood Tests in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 40 studies on Alzheimer's Blood Tests that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how alzheimer's Blood Tests products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Biomarker
4.2 By Use
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 C2N Diagnostics
7.2 Roche Diagnostics
7.3 Fujirebio
7.4 Quanterix
7.5 Quest Diagnostics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The alzheimer's Blood Tests market can be segmented based on various criteria, including biomarker, use and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Alzheimer's Blood Tests right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Alzheimer's Blood Tests in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
How big is the Alzheimer's Blood Tests market in the US?
Placeholder estimate: about $174.6 Mn in 2025, rising to about $1.13 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Alzheimer's Blood Tests market in the US growing?
Placeholder estimate: about 23.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Alzheimer's Blood Tests market report cover?
The report splits the market by biomarker (p-Tau217, Amyloid Beta 42/40, Neurofilament Light), use (Diagnosis, Clinical Trial Screening, Monitoring) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Alzheimer's Blood Tests market?
Key players include C2N Diagnostics, Roche Diagnostics, Fujirebio, Quanterix and Quest Diagnostics.
What is driving the Alzheimer's Blood Tests market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.
Who regulates Alzheimer's Blood Tests in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Alzheimer's Blood Tests are running in the US?
40 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Alzheimer's Blood Tests?
PubMed lists 504 papers on Alzheimer's Blood Tests added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.